Loading company
CorMedix Inc.
CRMD · Nasdaq · ·
Next earnings: November 11, 2026
$7.94+0.5%Sep 29 close
- 1M
- -4.3%
- 6M
- +20.9%
- 1Y
- -31.7%
- 5Y
- +66.8%
CRMD · Nasdaq · ·
Next earnings: November 11, 2026
$7.94+0.5%Sep 29 close
CorMedix Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $101.9M | $39.7M | +156.52% |
| Profit | $26M | $19.8M | +31.07% |
| Profit per share | $0.29 | $0.28 | +3.57% |
| Free Cash Flow | $85.7M | $30M | +185.90% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from CorMedix Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
CorMedix Inc. has no earnings call transcript available.